Biogen signs molecular glue deal, raises yearly projectionsnews2024-10-30T11:26:16+00:00October 30th, 2024|Endpoints News|
Updated: Lilly’s shares tank after trimming revenue guidance. It also cut three assetsnews2024-10-30T11:16:18+00:00October 30th, 2024|Endpoints News|
GSK remains ‘very confident’ in RSV vaccine amid competition, sales slumpnews2024-10-30T10:59:39+00:00October 30th, 2024|Endpoints News|
Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’news2024-10-29T20:05:18+00:00October 29th, 2024|Endpoints News|
What would RFK Jr. do on healthcare? Trump ally’s FDA plans raise alarmnews2024-10-29T19:21:34+00:00October 29th, 2024|Endpoints News|
FDA again questions Lexicon diabetes drug ahead of adcommnews2024-10-29T18:32:24+00:00October 29th, 2024|Endpoints News|
Novartis expands Scemblix label to first-line CML patientsnews2024-10-29T18:10:50+00:00October 29th, 2024|Endpoints News|
Shionogi touts topline data for Covid-19 antiviral for post-exposure treatmentnews2024-10-29T17:49:42+00:00October 29th, 2024|Endpoints News|
Novartis highlights overall M&A track record following MorphoSys impairmentnews2024-10-29T17:02:34+00:00October 29th, 2024|Endpoints News|
In bid to lower ARIA-E, Eli Lilly tries a different dosing regimen for its Alzheimer’s drugnews2024-10-29T16:00:42+00:00October 29th, 2024|Endpoints News|
